In order to open the first Prime Site in Israel, IQVIA and Clalit Health Services have entered into a long-term partnership.

The alliance will combine the Israel pharmaceutical market data, and genomics expertise of IQVIA and Clalit.

The partnership will help focus on the future of innovation, such as data-powered clinical trial delivery and precision treatment, by combining these capabilities.
Alistair Grenfell, president of IQVIA Europe, the Middle East, Africa, and South Asia, stated: With Clalit, a healthcare organization that is both innovative and well-established, IQVIA is thrilled to open its first Prime Site in Israel.

"The work done as a result of this collaboration will change healthcare and pharmaceutical research for Israel and the rest of the world, resulting in improved patient outcomes."

The alliance aids IQVIA in meeting pharma interest in the nation as a premier stop for innovation and research, with the goal of transforming data insights based on electronic medical records into improved policy and healthcare.

Additionally, the Prime Site guarantees that the organization can offer Israeli pharmaceutical and biotech companies a local solution.

Eli Cohen, acting general director of Clalit Health Services, stated: Clalit, Israel's largest health organization, will now make use of its Prime Site status to provide our patients with access to the most cutting-edge therapies currently in development.

To know about the assumptions considered for the study, Download for Free Sample Report

"Our work together will help unlock further understanding of pharmaceutical and healthcare developments in the real world through the use of data and strategic delivery of research and care."

Over 1,600 primary care clinics and 14 hospitals are part of Clalit's network.

The Clinical Data Analytics Suite, IQVIA's software-as-a-service (SaaS) clinical data analytics platform for smarter and faster trials, was unveiled in June of last year.